Back to Search Start Over

Long-acting microneedle formulations.

Authors :
Vora LK
Sabri AH
Naser Y
Himawan A
Hutton ARJ
Anjani QK
Volpe-Zanutto F
Mishra D
Li M
Rodgers AM
Paredes AJ
LarraƱeta E
Thakur RRS
Donnelly RF
Source :
Advanced drug delivery reviews [Adv Drug Deliv Rev] 2023 Oct; Vol. 201, pp. 115055. Date of Electronic Publication: 2023 Aug 17.
Publication Year :
2023

Abstract

The minimally-invasive and painless nature of microneedle (MN) application has enabled the technology to obviate many issues with injectable drug delivery. MNs not only administer therapeutics directly into the dermal and ocular space, but they can also control the release profile of the active compound over a desired period. To enable prolonged delivery of payloads, various MN types have been proposed and evaluated, including dissolving MNs, polymeric MNs loaded or coated with nanoparticles, fast-separable MNs hollow MNs, and hydrogel MNs. These intricate yet intelligent delivery platforms provide an attractive approach to decrease side effects and administration frequency, thus offer the potential to increase patient compliance. In this review, MN formulations that are loaded with various therapeutics for long-acting delivery to address the clinical needs of a myriad of diseases are discussed. We also highlight the design aspects, such as polymer selection and MN geometry, in addition to computational and mathematical modeling of MNs that are necessary to help streamline and develop MNs with high translational value and clinical impact. Finally, up-scale manufacturing and regulatory hurdles along with potential avenues that require further research to bring MN technology to the market are carefully considered. It is hoped that this review will provide insight to formulators and clinicians that the judicious selection of materials in tandem with refined design may offer an elegant approach to achieve sustained delivery of payloads through the simple and painless application of a MN patch.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2023. Published by Elsevier B.V.)

Details

Language :
English
ISSN :
1872-8294
Volume :
201
Database :
MEDLINE
Journal :
Advanced drug delivery reviews
Publication Type :
Academic Journal
Accession number :
37597586
Full Text :
https://doi.org/10.1016/j.addr.2023.115055